Come-back for Lilly’s breast cancer drug
An experimental breast cancer combination being developed by Eli Lilly has hit its key goal of extending progression-free survival (PFS) in certain patients with advanced disease.
Read More
Tag: Monarch 2
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
- Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
